Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention. METHODS: To compare prasugrel, a new thienopyridine, with clopidogrel, we randomly assigned 13,608 patients with moderate-to-high-risk acute coronary syndromes with scheduled percutaneous coronary intervention to receive prasugrel (a 60-mg loading dose and a 10-mg daily maintenance dose) or clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose), for 6 to 15 months. The primary efficacy end point was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The key safety end point was major bleeding. RESULTS: The primary efficacy end point occurred in 12.1% of patients receiving clopidogrel and 9.9% of patients receiving prasugrel (hazard ratio for prasugrel vs. clopidogrel, 0.81; 95% confidence interval [CI], 0.73 to 0.90; P<0.001). We also found significant reductions in the prasugrel group in the rates of myocardial infarction (9.7% for clopidogrel vs. 7.4% for prasugrel; P<0.001), urgent target-vessel revascularization (3.7% vs. 2.5%; P<0.001), and stent thrombosis (2.4% vs. 1.1%; P<0.001). Major bleeding was observed in 2.4% of patients receiving prasugrel and in 1.8% of patients receiving clopidogrel (hazard ratio, 1.32; 95% CI, 1.03 to 1.68; P=0.03). Also greater in the prasugrel group was the rate of life-threatening bleeding (1.4% vs. 0.9%; P=0.01), including nonfatal bleeding (1.1% vs. 0.9%; hazard ratio, 1.25; P=0.23) and fatal bleeding (0.4% vs. 0.1%; P=0.002). CONCLUSIONS: In patients with acute coronary syndromes with scheduled percutaneous coronary intervention, prasugrel therapy was associated with significantly reduced rates of ischemic events, including stent thrombosis, but with an increased risk of major bleeding, including fatal bleeding. Overall mortality did not differ significantly between treatment groups. (ClinicalTrials.gov number, NCT00097591 [ClinicalTrials.gov].)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In patients with ACS undergoing PCI, 12 months' DAPT with low-dose ASA and prasugrel or ticagrelor was superior to DAPT with clopidogrel in the diabetes sub-group of the respective RCTs, with a benefit-risk profile similar to the overall trial populations (Supplementary data online, Tables S12-13).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [310]
In the citing paper
“With prasugrel, the primary efficacy endpoint occurred in 9.9% of patients as compared with 12.1% receiving clopidogrel (HR 0.81, 95% CI 0.73-0.90;P , 0.001).The risk of major bleeding was increased with prasugrel.501”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [501]
In the citing paper
“With ticagrelor given for 12 months the composite endpoint of death from vascular causes, myocardial infarction, or stroke occurred in 9.8% as compared with 11.7% of those receiving clopidogrel (HR 0.84, 95% CI 0.77-0.92;P , 0.001).No significant difference in rate of major bleeding was found.501 -503”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [501]
In the citing paper
“In patients with ACS for whom an early invasive strategy is planned, dual antiplatelet therapy with a P2Y12 inhibitor (ticagrelor or prasugrel) added to aspirin was superior to clopidogrel and aspirin.”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [501]
Citations
Cites
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Antman, E. M., Cohen, M., Bernink, P. J. L. M., McCabe, C. H., Horacek, T., Papuchis, G., Mautner, B., Corbalan, R., Radley, D., & Braunwald, E. (2000) · JAMA · doi:10.1001/jama.284.7.835 · Cited by 3,242
Self-citationSteinhubl, S. R., Berger, P. B., Mann III, J. T., Fry, E. T. A., DeLago, A., Wilmer, C., Topol, E. J., & for the CREDO Investigators (2002) · JAMA · doi:10.1001/jama.288.19.2411 · Cited by 3,078
Diener, H.-C., Bogousslavsky, J., Brass, L. M., Cimminiello, C., Csiba, L., Kaste, M., Leys, D., Matias-Guiu, J., & Rupprecht, H.-J. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16721-4 · Cited by 2,275
WRITING COMMITTEE MEMBERS, Smith, S. C., Feldman, T. E., Hirshfeld, J. W., Jacobs, A. K., Kern, M. J., King, S. B., Morrison, D. A., O’Neill, W. W., Schaff, H. V., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.170815 · Cited by 2,218
Self-citationSabatine, M. S., Cannon, C. P., Gibson, C. M., López-Sendón, J. L., Montalescot, G., Theroux, P., Claeys, M. J., Cools, F., Hill, K. A., Skene, A. M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050522 · Cited by 1,924
Self-citation(2005) · The Lancet · doi:10.1016/s0140-6736(05)67660-x · Cited by 1,858
Guidelines for Percutaneous Coronary Interventions
Silber, S., Albertsson, P., Avilés, F. F., Camici, P. G., Colombo, A., Hamm, C., Jørgensen, E., Marco, J., Nordrehaug, J.-E., Ruzyllo, W., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi138 · Cited by 1,609
Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting Stents
Mauri, L., Hsieh, W.-H., Massaro, J. M., Ho, K. K. L., D'Agostino, R., & Cutlip, D. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067731 · Cited by 1,441
Research works printed but not linked: 1
- Varenhorst C, 2007, Eur Heart J, 28, 189
Cited by
Items 401–500 of 1,004
Antithrombotic Therapy in the Elderly
Capodanno, D., & Angiolillo, D. J. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.04.063 · Cited by 152
Aradi, D., Komócsi, A., Price, M. J., Cuisset, T., Arı, H., Hazarbasanov, D., Trenk, D., Sibbing, D., Valgimigli, M., & Bonello, L. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.05.100 · Cited by 152
Murphy, S. A., Antman, E. M., Wiviott, S. D., Weerakkody, G. J., Morocutti, G., Huber, K., López-Sendón, J., McCabe, C. H., Braunwald, E., & for the TRITON-TIMI 38 Investigators (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn362 · Cited by 141
“A total of 13 608 patients with an acute coronary syndrome (both UA/NSTEMI and STEMI) for whom a PCI was planned were enrolled in TRITON-TIMI 38 and were randomized to prasugrel (loading dose of 60 mg and daily maintenance dose of 10 mg) or the approved regimen of clopidogrel (300 mg loading dose and 75 mg daily maint…”
BackgroundMethodInfluentialSelf-citationProton pump inhibitors: potential adverse effects
Abraham, N. S. (2012) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e328358d5b9 · Cited by 140
Biondi‐Zoccai, G., Lotrionte, M., Agostoni, P., Abbate, A., Romagnoli, E., Sangiorgi, G., Angiolillo, D. J., Valgimigli, M., Testa, L., Gaita, F., et al. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.08.035 · Cited by 140
P2Y12 receptors in platelets and other hematopoietic and non-hematopoietic cells
Gachet, C. (2012) · Purinergic Signalling · doi:10.1007/s11302-012-9303-x · Cited by 157
“52 % decreased Stent thrombosis [117], but with a 32 % increase of major bleeding, including fatal bleed-”
BackgroundPharmacogenetics to guide cardiovascular drug therapy
Duarte, J. D., & Cavallari, L. H. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00549-w · Cited by 161
P2Y12 platelet inhibition in clinical practice
Damman, P., Woudstra, P., Kuijt, W. J., de Winter, R. J., & James, S. K. (2011) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-011-0667-5 · Cited by 140
“The overall positive results from the JUMBO-TIMI 26 trial resulted in a large phase III efficacy and safety trial, the TRITONTIMI (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel—TIMI) 38 [32].”
BackgroundDrapkina, O. M., Васильевна, К. А., Калинина, А. М., Avdeev, S. M., Викторович, А. М., Alexandrova, L. M., Анциферова, А. А., Dm, A., Ахмеджанов, Н. М., Balanova, Y. А., et al. (2022) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2022-3235 · Cited by 233
Makki, N. M., Brennan, T. M. H., & Girotra, S. R. (2013) · Journal of Intensive Care Medicine · doi:10.1177/0885066613503294 · Cited by 150
“Rupture of an atherosclerotic plaque that results in partial or complete occlusion of an epicardial coronary artery is the most common mechanism responsible for ACS.”
BackgroundInfluentialAntibody-Based Ticagrelor Reversal Agent in Healthy Volunteers
Bhatt, D. L., Pollack, C. V., Weitz, J. I., Jennings, L. K., Xu, S., Arnold, S. E., Umstead, B. R., Mays, M. C., & Lee, J. S. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901778 · Cited by 140
Adenosine and the Cardiovascular System
Reiss, A. B., Grossfeld, D. J., Kasselman, L. J., Renna, H. A., Vernice, N. A., Drewes, W., Konig, J., Carsons, S. E., & DeLeon, J. R. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00345-5 · Cited by 157
Roffi, M., Patrono, C., Collet, J., Mueller, C. E., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2015) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2015.10.009 · Cited by 148
2020 Clinical practice guidelines for Acute coronary syndrome without ST segment elevation
Барбараш, О. Л., Duplyakov, D. V., Zateischikov, D. A., Панченко, Е. П., Shakhnovich, R. M., Yavelov, I. S., Yakovlev, A. N., Sa, A., Alekyan, B. G., Викторович, А. М., et al. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4449 · Cited by 149
Aleil, B., Jacquemin, L., de Poli, F., Zaehringer, M., Collet, J., Montalescot, G., Cazenave, J., Dickele, M.-C., Monassier, J., & Gachet, C. (2008) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2008.09.004 · Cited by 134
Self-citationP2 receptors and platelet function
Hechler, B., & Gachet, C. (2011) · Purinergic Signalling · doi:10.1007/s11302-011-9247-6 · Cited by 134
“decreased stent thrombosis [114], but with a 32% increase of major bleeding, including fatal bleeding.”
BackgroundHigh on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study
Silvain, J., Cayla, G., Hulot, J., Finzi, J., Kernéis, M., O’Connor, S. A., Bellemain-Appaix, A., Barthélémy, O., Beygui, F., Collet, J. ‐., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr407 · Cited by 139
Self-citationRoe, M. T., Goodman, S. G., Ohman, E. M., Stevens, S. R., Hochman, J. S., Gottlieb, S., Martínez, F. A., Dalby, A. J., Boden, W. E., White, H. D., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.002303 · Cited by 149
Self-citationNanhwan, M. K., Ling, S., Kodakandla, M., Nylander, S., Ye, Y., & Birnbaum, Y. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.304002 · Cited by 142
Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review
Kamran, H., Jneid, H. M., Kayani, W. T., Virani, S. S., Levine, G. N., Nambi, V., & Khalid, U. (2021) · JAMA · doi:10.1001/jama.2021.0716 · Cited by 153
Jolly, S. S., Pogue, J., Haladyn, K., Peters, R. J. G., Fox, K. A. A., Avezum, A., Gersh, B. J., Rupprecht, H. J., Yusuf, S., & Mehta, S. R. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn417 · Cited by 133
“The avoidance of major bleeding is important in the management of ACS, especially with more potent antiplatelet agents such as prasugrel.(28) Our study suggests that replacing the routine use of high-dose aspirin with lower doses of aspirin will reduce the risk of major bleeding by 20–25% and enhance the net efficacy–…”
BackgroundRandomized Trial of Atopaxar in the Treatment of Patients With Coronary Artery Disease
Wiviott, S. D., Flather, M. D., O’Donoghue, M. L., Goto, S., Fitzgerald, D. J., Cura, F. A., Aylward, P. E., Guetta, V., Dudek, D., Contant, C. F., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.001404 · Cited by 133
Self-citationSchiele, F., Gale, C. P., Bonnefoy, E., Capuano, F., Claeys, M. J., Danchin, N., Fox, K. A., Huber, K., Iakobishvili, Z., Lettino, M., et al. (2017) · European Heart Journal: Acute Cardiovascular Care · doi:10.1177/2048872616643053 · Cited by 132
G-Protein–Coupled Receptors as Signaling Targets for Antiplatelet Therapy
Smyth, S. S., Woulfe, D. S., Weitz, J. I., Gachet, C., Conley, P. B., Goodman, S. G., Roe, M. T., Kuliopulos, A., Moliterno, D. J., French, P. A., et al. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.176388 · Cited by 142
Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk
Kearney, K., Tomlinson, D., Smith, K., & Ajjan, R. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0515-9 · Cited by 130
“A prime example is the TRITON study that has shown that the combination of prasugrel and aspirin is superior to clopidogrel and aspirin at reducing vascular ischaemia following myocardial infarction but there was an increased risk of bleeding with the former combination making widespread clinical use problematic [33].”
BackgroundEmpey, P. E., Stevenson, J. M., Tuteja, S., Weitzel, K. W., Angiolillo, D. J., Beitelshees, A. L., Coons, J. C., Duarte, J. D., Franchi, F., Jeng, L. J. B., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1006 · Cited by 132
Luca, G. D., Bellandi, F., Huber, K., Noc, M., Petronio, A. S., Arntz, H. R., Maioli, M., Gabriel, H. M., Zorman, S., Carlo, M. D., et al. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04513.x · Cited by 131
Guedeney, P., Claessen, B. E., Kalkman, D. N., Aquino, M., Sorrentino, S., Giustino, G., Farhan, S., Vogel, B., Sartori, S., Montalescot, G., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.077 · Cited by 129
Self-citationCurrent concepts and novel targets for antiplatelet therapy
Gawaz, M., Geisler, T., & Borst, O. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00854-6 · Cited by 148
Bedside Evaluation of Thienopyridine Antiplatelet Therapy
Price, M. J. (2009) · Circulation · doi:10.1161/circulationaha.107.696732 · Cited by 138
Morel, O., Ghannudi, S. E., Jesel, L., Rădulescu, B. C., Meyer, N., Wiesel, M.-L., Caillard, S., Campia, U., Moulin, B., Gachet, C., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.09.032 · Cited by 131
McCarthy, C. P., Steg, P. G., & Bhatt, D. L. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx531 · Cited by 142
Left Ventricular Post-Infarct Remodeling
van der Bijl, P., Abou, R., Goedemans, L., Gersh, B. J., Holmes, D. R., Marsan, N. A., Delgado, V., & Bax, J. J. (2019) · JACC Heart Failure · doi:10.1016/j.jchf.2019.08.014 · Cited by 138
JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias
Ono, K., Iwasaki, Y., Akao, M., Ikeda, T., Ishii, K., Inden, Y., Kusano, K., Kobayashi, Y., Koretsune, Y., Sasano, T., et al. (2022) · Circulation Journal · doi:10.1253/circj.cj-20-1212 · Cited by 155
Ticagrelor — Is There Need for a New Player in the Antiplatelet-Therapy Field?
Schömig, A. (2009) · New England Journal of Medicine · doi:10.1056/nejme0906549 · Cited by 130
James, S. K., Storey, R. F., Khurmi, N. S., Husted, S., Keltai, M., Mahaffey, K. W., Maya, J. F., Morais, J., Lópes, R. D., Nicolau, J. C., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.082727 · Cited by 129
Roy, P. K., Bonello, L., Torguson, R., de Labriolle, A., Lemesle, G., Slottow, T. L. P., Steinberg, D. H., Kaneshige, K., Xue, Z., Satler, L. F., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.07.063 · Cited by 129
Kwok, C. S., Khan, M. A., Rao, S. V., Kinnaird, T. D., Sperrin, M., Buchan, I. E., de Belder, M., Ludman, P., Nolan, J., Loke, Y. K., et al. (2015) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.114.001645 · Cited by 128
Rahimi, K., Malhotra, A., Banning, A. P., & Jenkinson, C. (2010) · BMJ · doi:10.1136/bmj.c5707 · Cited by 128
“Patient reported outcomes were judged to be important in 81 of the trials (20%), of which 15 reported such outcomes. The majority of these were superiority trials that had used mostly patient important outcomes but had not adequately measured harms or had included a patient population with chronic symptoms. Studies th…”
Bonello, L., Mancini, J., Pansiéri, M., Maillard, L., ROSSI, P., Collet, F., Jouve, B., Wittenberg, O., Laine, M., Michelet, P., et al. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2012.04875.x · Cited by 130
Pocock, S., Mehran, R., Clayton, T. C., Nikolsky, E., Parise, H., Fahy, M. P., Lansky, A. J., Bertrand, M. E., Lincoff, A. M., Moses, J. W., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.878017 · Cited by 128
Composite End Points in Clinical Research: A Time for Reappraisal
Armstrong, P. W., & Westerhout, C. M. (2017) · Circulation · doi:10.1161/circulationaha.117.026229 · Cited by 141
Angiolillo, D. J., Galli, M., Alexopoulos, D. K., Aradi, D., Bhatt, D. L., Bonello, L., Capodanno, D., Cavallari, L. H., Collet, J., Cuisset, T., et al. (2024) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2024.08.027 · Cited by 157
Self-citationRollini, F., Franchi, F., Hu, J., Kureti, M., Aggarwal, N. R., Durairaj, A., Park, Y., Seawell, M., Cox‐Alomar, P. R., Zenni, M. M., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.02.045 · Cited by 132
“Compared with clopidogrel, prasugrel has more prompt, potent, and predictable antiplatelet effects, which in turn leads to a greater reduction in atherothrombotic events in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) (2,3).”
BackgroundInfluentialCuisset, T., Cayla, G., Frere, C., Quilici, J., Poyet, R., Gaborit, B., Bali, L., Morange, P., Alessi, M.-C., & Bonnet, J.-L. (2009) · EuroIntervention · doi:10.4244/51 · Cited by 125
Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients
Muhlestein, J. B. (2009) · Thrombosis and Haemostasis · doi:10.1160/th09-03-0177 · Cited by 134
“The combination of aspirin and clopidogrel is also effective in patients with ACS or those undergoing PCI (57, 72–76) (Table 2).”
BackgroundInfluentialManagement of Antithrombotic Therapy after Acute Coronary Syndromes
Rodríguez, F., & Harrington, R. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmra1607714 · Cited by 144
Price, M. J., Berger, P. B., Angiolillo, D. J., Teirstein, P. S., Tanguay, J., Kandzari, D. E., Cannon, C. P., & Topol, E. J. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.02.012 · Cited by 126
Alexopoulos, D. K., Dimitropoulos, G., Davlouros, P. A., Xanthopoulou, I., Kassimis, G., Stavrou, E. F., Hahalis, G. N., & Athanassiadou, A. (2011) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2010.12.011 · Cited by 125
Ibrahim, K. S., Christoph, M., Schmeinck, S., Schmieder, K., Steiding, K., Schoener, L., Pfluecke, C., Quick, S., Mues, C. A., Jellinghaus, S., et al. (2014) · Resuscitation · doi:10.1016/j.resuscitation.2014.02.004 · Cited by 130
Spaulding, C. M., Teíger, E., Commeau, P., Varenne, O., Bramucci, E., Slama, M., Beatt, K., Tirouvanziam, A. M., Poloński, L., Stella, P. R., et al. (2011) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2010.10.007 · Cited by 124
Kazi, D. S., Leong, T. K., Chang, T. I., Solomon, M. D., Hlatky, M. A., & Go, A. S. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.01.047 · Cited by 127
Part 9: Acute Coronary Syndromes
O’Connor, R. E., Ali, A. S., Brady, W. J., Ghaemmaghami, C. A., Menon, V., Welsford, M., & Shuster, M. (2015) · Circulation · doi:10.1161/cir.0000000000000263 · Cited by 145
Nicolau, J. C., Feitosa, G. S., Petriz, J. L. F., Furtado, R. H. D. M., Précoma, D. B., Lemke, W., Lópes, R. D., Timerman, A., Marin‐Neto, J. A., Bezerra, L., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210180 · Cited by 322
Protective Effects of Ticagrelor on Myocardial Injury After Infarction
Vilahur, G., Gutiérrez, M., Casaní, L., Varela, L. M., Capdevila, A., Pons‐Lladó, G., Carreras, F., Carlsson, L. G., Hidalgo, A., & Badimón, L. (2016) · Circulation · doi:10.1161/circulationaha.116.024014 · Cited by 128
Dayoub, E. J., Seigerman, M. E., Tuteja, S., Kobayashi, T., Kolansky, D. M., Giri, J. S., & Groeneveld, P. W. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.0783 · Cited by 133
Committees, T. T. C. E. A. S. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.07.001 · Cited by 128
Hagihara, K., Kazui, M., Kurihara, A., Yoshiike, M., Honda, K., Okazaki, O., Farid, N. A., & Ikeda, T. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.028498 · Cited by 124
“Prasugrel is shown to reduce the rate of thrombotic cardiovascular events and stent thrombosis in patients with acute coronary syndrome and those to be managed with percutaneous coronary intervention (Wiviott et al., 2007).”
BackgroundChin, C. T., Roe, M. T., Fox, K. A. A., Prabhakaran, D., Marshall, D. A., Petitjean, H., Lokhnygina, Y. V., Brown, E., Armstrong, P. W., White, H. D., et al. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.04.022 · Cited by 123
The prothrombotic state in atrial fibrillation: pathophysiological and management implications
Khan, A. A., & Lip, G. Y. H. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy272 · Cited by 139
Angiolillo, D. J. (2012) · Drugs · doi:10.2165/11640880-000000000-00000 · Cited by 134
Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents
Natarajan, A., Zaman, A., & Marshall, S. M. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.023 · Cited by 134
Payne, C. D., Li, Y. G., Brandt, J. T., Small, D. S., Farid, N. A., Salazar, D. E., Winters, K. J., & Jakubowski, J. A. (2008) · Thrombosis and Haemostasis · doi:10.1160/th07-09-0575 · Cited by 122
“The phase 3 study of prasugrel (TRITON-TIMI 38) has recently been reported (8).”
BackgroundCarboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators
Her, L., & Zhu, H. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.089680 · Cited by 131
“Moreover, phenobarbital induced CES1 expression in mouse livers, and the inducibility was more prominent in neonatal mice relative to adult mice (Xiao et al., 2012).”
BackgroundAspirin and antiplatelet treatments in cancer
Tao, D. L., Yunga, S. T., Williams, C. D., & McCarty, O. J. T. (2021) · Blood · doi:10.1182/blood.2019003977 · Cited by 133
Platelet-Cancer Interplay: Molecular Mechanisms and New Therapeutic Avenues
Braun, A., Anders, H., Gudermann, T. W., & Mammadova‐Bach, E. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.665534 · Cited by 142
Dangas, G., Claessen, B. E. P. M., Mehran, R., Xu, K., Fahy, M. P., Parise, H., Henriques, J. P. S., Ohman, E. M., White, H. D., & Stone, G. W. (2012) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2012.07.012 · Cited by 121
2-Year Outcomes of High Bleeding Risk Patients After Polymer-Free Drug-Coated Stents
Garot, P., Morice, M., Tresukosol, D., Pocock, S., Meredith, I. T., Abizaid, A., Carrié, D., Naber, C. K., Íñiguez, A., Talwar, S., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.10.009 · Cited by 125
The Role of Clopidogrel in 2020: A Reappraisal
Patti, G., Micieli, G., Cimminiello, C., & Bolognese, L. (2020) · Cardiovascular Therapeutics · doi:10.1155/2020/8703627 · Cited by 151
“Bleeding risk is of particular concern in elderly patients, who represent a large proportion of patients with ACS; however, this patient population was underrepresented in the PLATO and TRITON trials [16, 17].”
BackgroundIsshiki, T., Kimura, T., Ogawa, H., Yokoi, H., Nanto, S., Takayama, M., Kitagawa, K., Nishikawa, M., Miyazaki, S., Ikeda, Y., et al. (2014) · Circulation Journal · doi:10.1253/circj.cj-14-0266 · Cited by 120
Clopidogrel response variability: Current status and future directions
Ferreiro, J. L., & Angiolillo, D. J. (2009) · Thrombosis and Haemostasis · doi:10.1160/th09-03-0185 · Cited by 121
Bell, A., Roussin, A., Cartier, R., Chan, W., Douketis, J. D., Gupta, A. K., Kraw, M. E., Lindsay, T. F., Love, M. P., Pannu, N., et al. (2011) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2010.12.015 · Cited by 127
Price, M., Walder, J. S., Baker, B. A., Heiselman, D., Jakubowski, J., Logan, D. K., Winters, K., Li, W., & Angiolillo, D. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.02.042 · Cited by 123
“Among atients who underwent CABG in the TRITON-TIMI 38 rial, the rate of CABG-related bleeding was significantly reater with prasugrel compared with clopidogrel, and this ncreased risk persisted up to 7 days from the most recent dose f study drug (5).”
BackgroundBaber, U., Dangas, G., Cohen, D. J., Gibson, C. M., Mehta, S. R., Angiolillo, D. J., Pocock, S., Krucoff, M. W., Kastrati, A., Ohman, E. M., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.09.006 · Cited by 125
Self-citationWiviott, S. D., Antman, E. M., & Braunwald, E. (2010) · Circulation · doi:10.1161/circulationaha.109.921502 · Cited by 122
Self-citationSiller-Matula, J. M., Krumphuber, J., & Jilma, B. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00555.x · Cited by 116
“The TRITON-TIMI 38 trial was a double-blind, parallel group study comparing prasugrel (LD 60 mg, MD 10 mg) with clopidogrel (LD 300 mg, MD 75 mg) in >13 000 patients with ACS undergoing PCI (Wiviott et al., 2007a; Murphy et al., 2008; Montalescot et al., 2009).”
BackgroundMethodCombination Antithrombotic Therapies
Gurbel, P. A., & Tantry, U. S. (2010) · Circulation · doi:10.1161/circulationaha.109.853085 · Cited by 127
Akbari, S. H. A., Reynolds, M. R., Kadkhodayan, Y., Cross, D. T., & Moran, C. J. (2012) · Journal of NeuroInterventional Surgery · doi:10.1136/neurintsurg-2012-010334 · Cited by 117
Part 9: Acute Coronary Syndromes
O’Connor, R. E., Bossaert, L. L., Arntz, H.-R., Brooks, S. C., Diercks, D., Feitosa-Filho, G. S., Nolan, J. P., Hoek, T. L. V., Walters, D., Wong, A., et al. (2010) · Circulation · doi:10.1161/circulationaha.110.985549 · Cited by 121
Patti, G., Pasceri, V., Vizzi, V., Ricottini, E., & Sciascio, G. D. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.11.025 · Cited by 120
Iannaccone, M., D’Ascenzo, F., Vadalà, P., Wilton, S. B., Noussan, P., Colombo, F., Raposeiras‐Roubín, S., Assi, E. A., González‐Juanatey, J. R., Henriques, J. P. S., et al. (2017) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872617706501 · Cited by 135
From Atherosclerotic Plaque to Myocardial Infarction—The Leading Cause of Coronary Artery Occlusion
Młynarska, E., Czarnik, W., Fularski, P., Hajdys, J., Majchrowicz, G., Stabrawa, M., Rysz, J., & Franczyk, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137295 · Cited by 191
“Based on trial results, dual-antiplatelet therapy (DAPT) consisting of aspirin and a P2Y12 receptor inhibitor is recommended for patients with ACS [97,98].”
BackgroundThe effect of optimal medical therapy on 1-year mortality after acute myocardial infarction
Bramlage, P., Messer, C., Bitterlich, N., Pohlmann, C., Cuneo, A., Stammwitz, E., Tebbenjohanns, J., Gohlke, H., Senges, J., & Tebbe, U. (2010) · Heart · doi:10.1136/hrt.2009.188607 · Cited by 115
“1%.(5) For the secondary prevention of vascular events clinical trials have shown that five drug classes substantially improve the prognosis of patients with acute myocardial infarction: aspirin, bblockers, statins, renin angiotensin system (RAS) blockers and thienopyridines.”
BackgroundHess, C. N., McCoy, L. A., Duggirala, H. J., Tavris, D. R., O’Callaghan, K. M., Douglas, P. S., Peterson, E. D., & Wang, T. Y. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000523 · Cited by 117
Anti‐platelet therapy: ADP receptor antagonists
Wijeyeratne, Y. D., & Heptinstall, S. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.03999.x · Cited by 120
Unstable Angina and Non–ST Elevation Myocardial Infarction
Braunwald, E. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201109-1745ci · Cited by 127
Velmurugan, S., Kapil, V., Ghosh, S. M., Davies, S., McKnight, A., Aboud, Z., Khambata, R. S., Webb, A. J., Poole, A., & Ahluwalia, A. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.06.031 · Cited by 114
“This first line treatment coupled with effective secondary prevention using aspirin and other antiplatelet drugs, such as prasugrel [54], have made substantial reductions in both mortality and morbidity.”
BackgroundPersonalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study
Siller-Matula, J. M., Francesconi, M., Dechant, C., Jilma, B., Maurer, G., Delle‐Karth, G., Gouya, G., Ruzicka, K., Podczeck-Schweighofer, A., & Christ, G. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.05.040 · Cited by 114
“On the other hand, enhanced efficacy of these antiplatelet drugs is associated with an increased risk of major bleedings [3,14,15,17].”
BackgroundGurbel, P. A., & Tantry, U. S. (2012) · Circulation · doi:10.1161/circulationaha.111.031195 · Cited by 120
Acute coronary syndrome in the Asia-Pacific region
Chan, M. Y., Du, X., Eccleston, D. S., Ma, C., Mohanan, P. P., Ogita, M., Shyu, K., Yan, B. P., & Jeong, Y. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.04.073 · Cited by 128
Casselman, F. P. A., Lance, M. D., Ahmed, A. B., Ascari, A., Blanco-Morillo, J., Bolliger, D., Eid, M., Erdoes, G., Haumann, R. G., Jeppsson, A., et al. (2024) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezae352 · Cited by 187
New P2Y12Inhibitors Versus Clopidogrel in Percutaneous Coronary Intervention
Bellemain-Appaix, A., Brieger, D. B., Beygui, F., Silvain, J., Peña, A., Cayla, G., Barthélémy, O., Collet, J., & Montalescot, G. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.07.012 · Cited by 112
Self-citationGurbel, P. A., Antonino, M. J., Bliden, K. P., DiChiara, J., Suarez, T., Singla, A., & Tantry, U. S. (2008) · Platelets · doi:10.1080/09537100802351065 · Cited by 112
Patti, G., Bárczi, G., Orlic, D. N., Mangiacapra, F., Colonna, G., Pasceri, V., Barbato, E., Merkely, B. P., Edes, I. F., Ostojić, M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.044 · Cited by 113
O’Donoghue, M. L., Antman, E. M., D, E. B. M., Murphy, S. A., Steg, P. G., Finkelstein, A., Penny, W. F., Fridrich, V., McCabe, C. H., Sabatine, M. S., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.05.025 · Cited by 113
“In RITON–TIMI 38, prasugrel significantly reduced the risk f recurrent CV events as compared with clopidogrel, both n the periprocedural period and during long-term ollow-up (5,21).”
Self-citationDuration of Dual Antiplatelet Therapy After Coronary Stenting
Montalescot, G., Brieger, D. B., Dalby, A. J., Park, S., & Mehran, R. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.05.053 · Cited by 115
Self-citationPerioperative management of antiplatelet therapy
Oprea, A. D., & Popescu, W. M. (2013) · British Journal of Anaesthesia · doi:10.1093/bja/aet402 · Cited by 121
Anticoagulation for Percutaneous Ventricular Assist Device-Supported Cardiogenic Shock
Vandenbriele, C., Arachchillage, D. J., Frederiks, P., Giustino, G., Gorog, D. A., Gramegna, M., Janssens, S. P., Meyns, B. P., Polzin, A., Scandroglio, M., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.02.052 · Cited by 113
Nylander, S., & Schulz, R. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13429 · Cited by 114
“Both prasugrel and ticagrelor provide superior clinical benefit compared with clopidogrel when given on top of aspirin in ACS patients (Wiviott et al., 2007; Wallentin et al., 2009).”
BackgroundEscaned, J., Cao, D., Baber, U., Nicolas, J., Sartori, S., Zhang, Z., Dangas, G., Angiolillo, D. J., Briguori, C., Cohen, D. J., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab702 · Cited by 119
Self-citation
Metadata
- Authors
- Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., Riesmeyer, J., Weerakkody, G., Gibson, C. M., & Antman, E. M.
- Affiliations
- Brigham and Women's Hospital (US)
- Inserm (FR)
- Bikur Cholim Hospital (IL)
- Universitäts-Herzzentrum Freiburg-Bad Krozingen (DE)
- Ospedale di Parma (IT)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-15
- Volume
- 357
- Issue
- 20
- Pages
- 2001-2015
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2169387542
- Cited by
- 6,790
- References
- 40
- Citations by year
- 2026: 162 · 2025: 202 · 2024: 187 · 2023: 265 · 2022: 309 · 2021: 326 · 2020: 339 · 2019: 361 · 2018: 389 · 2017: 418 · 2016: 419 · 2015: 465 · 2014: 448 · 2013: 502 · 2012: 507
- FWCI
- 238.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- prasugrel, clopidogrel, acute coronary syndrome, percutaneous coronary intervention, dual antiplatelet therapy, thienopyridines, major bleeding, stent thrombosis, myocardial infarction, target vessel revascularization, cardiovascular mortality, bleeding risk stratification, bleeding risk score
- MeSH terms
- Prasugrel Hydrochloride, Clopidogrel, Aged, Aspirin, Double-Blind Method, Drug Therapy, Combination, Female, Hemorrhage, Humans, Male, Middle Aged, Myocardial Infarction, Piperazines, Platelet Aggregation Inhibitors, Prodrugs, Thiophenes, Thrombosis, Ticlopidine, Angioplasty, Balloon, Coronary, Stroke, Kaplan-Meier Estimate, Acute Coronary Syndrome, Purinergic P2 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.